Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics Inc. shares AKRO fell more than 60% Tuesday after the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a form of fatty ...

Investing.com - TD Cowen initiated coverage on Akero Therapeutics (NASDAQ: AKRO) with a Buy rating and a $76.00 price target on Monday. The company, currently valued at $3.91 billion, has seen its ...

Akero Therapeutics Inc. advanced stock charts by Barron's. View 1AKRO historical stock data and compare to other stocks, and exchanges.

Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.